KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to $108.8 million.

  • Emergent BioSolutions' Depreciation & Amortization (CF) fell 11.36% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.3 million, marking a year-over-year decrease of 12.54%. This contributed to the annual value of $108.8 million for FY2024, which is 13.03% down from last year.
  • Per Emergent BioSolutions' latest filing, its Depreciation & Amortization (CF) stood at $108.8 million for FY2024, which was down 13.03% from $125.1 million recorded in FY2023.
  • Emergent BioSolutions' 5-year Depreciation & Amortization (CF) high stood at $143.3 million for FY2022, and its period low was $108.8 million during FY2024.
  • For the 3-year period, Emergent BioSolutions' Depreciation & Amortization (CF) averaged around $125.7 million, with its median value being $125.1 million (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first grew by 15.75% in 2022, then fell by 13.03% in 2024.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Depreciation & Amortization (CF) stood at $114.5 million in 2020, then increased by 8.12% to $123.8 million in 2021, then increased by 15.75% to $143.3 million in 2022, then decreased by 12.70% to $125.1 million in 2023, then declined by 13.03% to $108.8 million in 2024.